CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Vivo Bio Tech Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Vivo Bio Tech Ltd
608 6Th Floor
Lingapur Complex, Himayath Nagar
Phone: +91 4048199999p:+91 4048199999 HYDERABAD, 500034  India Ticker: 511509511509
Business Summary
Vivo Bio Tech Limited is a comprehensive pre-clinical clinical research organization (CRO) providing drug development and discovery services company. It operates in biotechnology segment. The Company offering drug development and discovery services to pharmaceutical and biotech companies. The Company offers services in the areas of in vivo and in vitro toxicity studies, pharmacological investigations, pharmacokinetic and toxic kinetic studies, genotoxicity screening, and analytical services. It provides both regulatory and non-regulatory IND enabling preclinical development services. The Company provides screening and evaluating molecules for various pharmacological and therapeutic properties. Specifically for oncology, it provides design and development of syngeneic / xenograft models for evaluation of anti-cancer agent. The Company also customizes In vivo drug metabolism and pharmacokinetics (DMPK) studies to help profile drug candidate in both rodent and non-rodent animal models.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20243/31/2024Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Financial Officer, Additional Whole-time Director KompellaSri Kalyan 11/3/2021 7/22/2010
Compliance Officer, Company Secretary Vaishnavi K.Ayinampudi 1/23/2024 1/23/2024
Whole Time Director M. KalyanRam 7/30/2013 7/30/2013
5 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 14,903,520 (As of 3/31/2024)
Stock Exchange: BOM
Fax Number: +91 4027890669


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, November 21, 2024